Russian pharma residents planning relocation face new tax exposure from 2026 changes. Structuring should be reviewed before any move. Make an enquiry.
For individuals in Russia's pharmaceuticals sector who are considering a change of tax residency, the opening months of 2026 bring a materially altered planning environment. A convergence of legislative amendments — including the restructured progressive personal income tax scale that took effect at the start of this year, tightened reporting requirements for controlled foreign companies held by Russian tax residents, and evolving Federal Tax Service guidance on the classification of assets characteristic of the pharmaceutical industry — has shifted the calculus for pre-immigration tax planning in Russia in ways that demand early, sector-informed review. What was a workable structuring window as recently as mid-2024 is narrowing in several respects, and the sequence in which residency and asset events occur now carries consequences that were less acute under the prior regime.
The most significant development for Russian pharma residents planning relocation is the full implementation of Russia's restructured personal income tax framework. Russia moved from a broadly flat personal income tax rate to a graduated scale, with the uppermost bands now applying to income above thresholds that many senior executives and business owners in the pharmaceutical sector will routinely exceed. For those who retain Russian tax residency into 2026 while generating substantial income from pharma assets — whether through dividend distributions from operating companies, royalty streams from registered intellectual property, or proceeds from the partial disposal of stakes — the effective rate exposure is materially higher than it was under the prior structure.
Alongside the rate changes, the Federal Tax Service has continued to refine its approach to the taxation of individuals who cease to be Russian tax residents during a calendar year. The prevailing regulatory position treats the year of departure as one requiring particular scrutiny: income that accrues or is recognised during the residency period is taxed as if the individual remained a Russian resident for the full relevant period in certain circumstances. For pharma sector professionals whose compensation arrangements include deferred elements — milestone payments tied to product approvals, performance-linked equity, or earn-out structures in connection with the sale of a pharmaceutical business — the timing of recognition relative to the date of departure is not a question that can be deferred to an accountant after the move has been made.
The controlled foreign company rules, already a structural feature of Russian tax law for several years, have been subject to further administrative tightening. Russian tax residents holding interests in foreign structures — including holding companies used to consolidate pharmaceutical assets, licensing entities holding drug dossiers or brand registrations in foreign markets, and trading entities in EAEU member states — are required to maintain detailed reporting and, in certain circumstances, to attribute the undistributed profits of those structures to their personal Russian tax base. The enforcement posture of the Federal Tax Service in this area has become more consistent, and the discretionary latitude that characterised earlier administrative practice has narrowed. For pharma sector individuals who have been operating with foreign holding structures under the assumption that pre-existing arrangements would not be re-examined, the 2026 environment warrants a fresh assessment.
The pharma sector is not uniform, and the planning considerations for a majority shareholder in a mid-size Russian pharmaceutical manufacturer differ substantially from those facing a senior executive with a significant equity stake, a specialist distributor with cross-border supply arrangements, or an individual whose wealth is concentrated in a portfolio of registered pharmaceutical intellectual property.
For business owners, the primary concern in any pre-immigration tax planning exercise is the valuation and treatment of their Russian operating assets at the point of departure. Russian law does not yet implement a fully codified exit tax in the sense understood in several European jurisdictions — a formal charge on unrealised gains arising at the moment residency is lost. However, the gap between the absence of a formal exit charge and practical tax neutrality is narrower than it appears. Where a departure is followed by a disposition of Russian assets, the Federal Tax Service has the analytical tools to scrutinise the sequence of events and to challenge arrangements in which value was extracted at favourable rates in anticipation of a departure that was already planned. Pharma assets — particularly registered trademarks, marketing authorisations, and other intangibles that may have been held within Russian entities at historic book values — are a category where a gap between carrying value and market value is both common and visible.
For executives and senior employees, the interaction between deferred compensation and departure timing is the dominant issue. Pharmaceutical companies operating in Russia — both domestic groups and subsidiaries of international manufacturers — frequently structure senior remuneration with deferred elements. Where those elements are denominated in or linked to the performance of a Russian entity, and where the individual plans to become a non-resident before the payment is received or vests, the applicable rate and the withholding mechanics are an area of active Federal Tax Service attention in 2026.
For individuals holding pharmaceutical intellectual property — whether registered in Russia under Rospatent, licensed from a foreign rights-holder, or held in a foreign structure that licenses into Russia — the intersection of IP valuation, transfer pricing, and the CFC attribution rules creates a planning environment that requires coordinated analysis rather than sequential advice. Russia's membership of EAEU arrangements introduces an additional layer: EAEU-coordinated positions on IP taxation and cross-border royalty flows mean that structures that were calibrated for a purely Russia-to-third-country analysis may not behave as expected where the intermediate jurisdiction is an EAEU member state.
For pharmaceutical sector individuals considering relocation from Russia, the structuring decisions made in advance of a change of residency are among the most consequential in any wealth planning exercise. We advise on Russian law aspects of pre-immigration planning — including CFC analysis, IP structuring, and the Russian tax treatment of deferred compensation — in coordination with the client's advisers in the destination jurisdiction. Discuss your matter in confidence: info@vetrovpartners.com |
Pre-immigration tax planning for Russian residents in the pharmaceuticals sector is, at its core, a sequencing problem. The question is not simply what the Russian tax exposure is at any given point, but in what order events should occur — and which events, once triggered, constrain or foreclose subsequent options. The 2026 regulatory developments have tightened several of those sequences.
The first consideration is residency timing. Russian tax residency is determined by physical presence in Russia for at least 183 days in a calendar year, subject to certain treaty provisions. The calendar-year structure means that a departure timed without regard to the residency count may result in an individual remaining a Russian tax resident for a full calendar year despite having physically left Russia. For individuals who also become tax residents of another jurisdiction — particularly a jurisdiction with which Russia has a double taxation treaty that modifies the standard 183-day test — the interaction between the two residency regimes is a threshold question that needs to be resolved early in the planning process.
The second consideration is asset sequencing. The disposal, restructuring, or transfer of pharma assets — including both operating company interests and intellectual property portfolios — has different tax consequences depending on whether the individual is a Russian tax resident or a non-resident at the relevant date. For assets where a significant valuation gap exists, a pre-departure analysis of whether a disposal before loss of residency is preferable to a post-departure disposal (taking account of applicable withholding rates and treaty relief) is not optional — it is the foundation of any credible plan.
The third consideration is CFC compliance. An individual who departs Russia without establishing a complete and defensible CFC reporting position — addressing all foreign structures in which they hold a direct or indirect interest above the relevant threshold — carries a compliance tail into their post-departure life that can complicate both their new residency position and any future dealings with Russian counterparties. For pharma sector individuals whose foreign holding structures include licensing entities, dossier-holding vehicles, or regional distribution arrangements, a CFC inventory conducted before departure is markedly easier than one conducted under administrative pressure after.
The fourth consideration is the treatment of Russian-source income that continues to arise after departure. Royalty flows from Russian pharmaceutical registrations, dividends from retained Russian operating entities, and service fees from Russian group companies paid to a non-resident individual or their foreign holding structure are all subject to Russian withholding tax at rates that vary according to the nature of the payment and the existence of a relevant double taxation treaty. Advisers who plan the departure without modelling the ongoing Russian-source income profile of their client are addressing only part of the picture.
Several areas relevant to pharma sector pre-immigration planning remain subject to interpretive uncertainty in early 2026.
The classification of pharmaceutical marketing authorisations and drug dossiers as assets for Russian tax purposes — and in particular their treatment under transfer pricing rules when transferred between related parties in anticipation of a departure — is an area where Federal Tax Service guidance has been issued in general terms but where sector-specific administrative practice is still developing. Advisers should be cautious about applying general IP transfer pricing principles to pharmaceutical regulatory assets without specialist review.
The interaction between Russia's CFC rules and the EAEU's evolving position on the tax treatment of structures in member states — including Kazakhstan, Belarus, and Armenia, which are commonly used as intermediate holding locations for pharma distribution and licensing — is a further area where the picture is not yet settled. Structures that were calibrated before the most recent EAEU-level coordination may need to be re-examined.
Finally, double taxation treaty networks relevant to common destination jurisdictions are not static. Russia has suspended the application of certain treaty provisions in respect of a number of jurisdictions, and any treaty-based planning assumption should be verified against the current treaty status before it is relied upon.
"
"Pharmaceutical assets are rarely straightforward for pre-immigration purposes: the gap between book value and market value in Russian pharma holdings, combined with the CFC reporting tail, means that sequencing matters more here than in almost any other sector."— Elizaveta Razina, Senior Lawyer, Practice Lead — IP Enforcement, Vetrov & Partners
"
Q: What specifically changed in the Russian tax framework affecting pre-immigration planning in 2026?
A: The most significant change is the full implementation of Russia's progressive personal income tax scale, which took effect at the start of 2026. The restructured rates mean that high-income individuals — including many in the pharmaceuticals sector — face a materially higher effective rate on income arising during any period in which they remain Russian tax residents. Alongside the rate changes, the Federal Tax Service has continued to tighten its administrative approach to CFC reporting obligations and to the scrutiny of income recognition during the year of departure. These changes do not alter the foundational rules of pre-immigration planning, but they raise the cost of sequencing errors and reduce the tolerance for arrangements that were calibrated under the prior rate structure.
Q: Which pharmaceutical sector individuals are most affected by these developments?
A: The developments are most acute for three groups. First, business owners holding significant interests in Russian pharmaceutical companies or IP portfolios, where a valuation gap between book value and market value is common and where the Federal Tax Service's scrutiny of pre-departure disposals has intensified. Second, senior executives and employees whose compensation includes deferred elements linked to Russian entity performance, where the timing of recognition relative to the departure date directly affects the applicable rate. Third, individuals holding pharmaceutical intellectual property — including drug registrations and marketing authorisations — in foreign structures subject to the CFC attribution rules, where the 2026 administrative environment is more demanding than it was in prior years.
Q: What should a pharmaceutical sector individual — or their adviser — do before initiating a residency change?
A: The practical priority is to conduct a structured pre-departure review that addresses four sequencing questions: when residency is lost relative to the calendar year; how Russian pharma assets are treated before and after that date; whether all foreign holding structures are CFC-compliant; and what the ongoing Russian-source income profile looks like post-departure. This review is most effective when conducted before any irreversible steps — asset transfers, corporate restructurings, or public announcements of relocation — have been taken. For the pharmaceuticals sector specifically, the review should include specialist analysis of any pharmaceutical IP and regulatory assets, given that general IP transfer pricing principles do not always map cleanly onto pharmaceutical marketing authorisations and drug dossiers.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry